Menopause  >>  Caprelsa (vandetanib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Caprelsa (vandetanib) / Sanofi
ZACFAST, NCT00752986 / 2008-000579-12: ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial

Terminated
2
39
Europe
ZD6474 (Vandetanib at the dose of 100 mg), Zactima, Placebo to match ZD6474 (Vandetanib at the dose of 100 mg), Fulvestrant, Faslodex, ZD6474 (Vandetanib at the dose of 300 mg), Placebo to match ZD6474 (Vandetanib at the dose of 300 mg)
Genzyme, a Sanofi Company
Breast Cancer
09/13
09/13

Download Options